Download Free Sample Report

The global Hospital-Acquired Disease Testing market was valued at US$ 506.5 million in 2022 and is projected to reach US$ 711.6 million by 2029, at a CAGR of 5.0% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Hospital acquired infections/diseases (HAIs) or nosocomial infections are defined to the infection acquired by patients during their stay in healthcare settings. Approximately 9.2 out of 100 patients in the U.S. acquire HAI. The most common types of HAIs include pneumonia, urinary tract infection, bloodstream infection, surgical site infection and others. HAIs are caused by pathogens among patients with compromised immune system, and negligence by hospital staff. The significant morbidity and mortality, the associated management costs and growing pressure from governing bodies have urged care-givers to devise accurate diagnosis of HAIs for efficient healthcare provision.
This report aims to provide a comprehensive presentation of the global market for Hospital-Acquired Disease Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hospital-Acquired Disease Testing. This report contains market size and forecasts of Hospital-Acquired Disease Testing in global, including the following market information:

• Global Hospital-Acquired Disease Testing Market Revenue, 2018-2023, 2024-2032, ($ millions)
• Global top five companies in 2022 (%)

The increasing incidence of hospital acquired infections (HAI) is one of the key factors propelling the global hospital acquired disease testing market. For the prevention of these infections many countries such as the U.S. have issued rules and regulations to be mounted in the hospitals and clinics. For instance, the U.S. has regulated HHS Action Plan to reduce infections auqired in hospitals. These government plans and movements and increasing investments are expected to poise to growth of the global market of hospital acquired disease testing. Furthermore, the rising number of pathogens with drug-resistant abilities is foreseen to help the market expand. Numerous hospitals around the world are facilitating the pathogen detection procedures with improved surveillance culture. To prevent the transmission of diseases, various health organizations are demanding for effective hospital acquired disease testing solutions.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hospital-Acquired Disease Testing companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hospital-Acquired Disease Testing Market, by Type, 2018-2023, 2024-2032 ($ millions)
Global Hospital-Acquired Disease Testing Market Segment Percentages, by Type, 2022 (%)

• UTI Testing
• SSI Testing
• Pneumococcal Infections Testing
• Bloodstream Infections Testing
• MRSA Testing

Global Hospital-Acquired Disease Testing Market, by Application, 2018-2023, 2024-2032 ($ millions)
Global Hospital-Acquired Disease Testing Market Segment Percentages, by Application, 2022 (%)

• Small and Medium Sized Hospitals
• Large Sized Hospitals

Global Hospital-Acquired Disease Testing Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions)
Global Hospital-Acquired Disease Testing Market Segment Percentages, By Region and Country, 2022 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hospital-Acquired Disease Testing revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Hospital-Acquired Disease Testing revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:

• Diatherix Laboratories
• Gen-Probe
• Qiagen
• F. Hoffmann-La Roche
• Cepheid
• Life Technologies Corporation
• Meridian Biosciences
• Cantel Medical Corporation
• Nordion

Outline of Major Chapters:

• Chapter 1: Introduces the definition of Hospital-Acquired Disease Testing, market overview.
• Chapter 2: Global Hospital-Acquired Disease Testing market size in revenue.
• Chapter 3: Detailed analysis of Hospital-Acquired Disease Testing company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
• Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
• Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
• Chapter 6: Sales of Hospital-Acquired Disease Testing in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
• Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
• Chapter 8: The main points and conclusions of the report.